Annexon Biosciences Overview

  • Founded
  • 2011

Founded
  • Status
  • Public

  • Employees
  • 83

Employees
  • Stock Symbol
  • ANNX

Stock Symbol
  • Share Price
  • $7.10

  • (As of Friday Closing)

Annexon Biosciences General Information

Description

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 1400 Sierra Point Parkway
  • Building C, 2nd Floor
  • Brisbane, CA 94005
  • United States
+1 (650) 000-0000

Annexon Biosciences Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Annexon Biosciences Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.10 $7.06 $2.06 - $8.20 $336M 47.6M 171K -$3.18

Annexon Biosciences Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 150,819 203,383 584,399
Revenue 0 0 0 0
EBITDA (144,280) (128,572) (62,802) (36,686)
Net Income (144,935) (130,323) (63,412) (37,183)
Total Assets 312,722 287,040 355,946 49,898
Total Debt 33,706 34,589 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Annexon Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Annexon Biosciences‘s full profile, request access.

Request a free trial

Annexon Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Annexon Biosciences‘s full profile, request access.

Request a free trial

Annexon Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with cla
Drug Discovery
Brisbane, CA
83 As of 2022
00000
000000000 00000

000000

t ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerci
0000000000000
Boston, MA
000 As of 0000
00000
000000 - 000 00000

000000

olor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut
0000 000000000
South San Francisco, CA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Annexon Biosciences Competitors (71)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rhythm Pharmaceuticals Formerly VC-backed Boston, MA 000 00000 000000 - 000 00000
0000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
0000000 0000000000 Pending Transaction (M&A) Lexington, MA 00 00000 000000&0 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
You’re viewing 5 of 71 competitors. Get the full list »

Annexon Biosciences Patents

Annexon Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220048930-A1 Inhibitors of complement factors and uses thereof Pending 20-Jul-2020 000000000
AU-2021311455-A1 Inhibitors of complement factors and uses thereof Pending 20-Jul-2020
AU-2021278819-A1 Compositions and methods for treating epilepsy Pending 05-May-2020 000000000
CA-3177879-A1 Compositions and methods for treating epilepsy Pending 05-May-2020
AU-2020365132-A1 Compositions and methods for treating blood disorders Pending 17-Oct-2019 C07K16/18
To view Annexon Biosciences’s complete patent history, request access »

Annexon Biosciences Executive Team (12)

Name Title Board Seat Contact Info
Douglas Love JD Chief Executive Officer & Board Member
Jennifer Lew Chief Financial Officer & Executive Vice President
Dean Artis Chief Scientific Officer
Larry Mattheakis Ph.D Chief Scientific Officer
Michael Overdorf Executive Vice President & Executive
You’re viewing 5 of 12 executive team members. Get the full list »

Annexon Biosciences Board Members (14)

Name Representing Role Since
Douglas Love JD Annexon Biosciences Chief Executive Officer & Board Member 000 0000
Jung Choi Annexon Biosciences Board Member 000 0000
Muneer Satter JD Satter Foundation Board Member 000 0000
Ricky Sun Ph.D Bain Capital Board Member 000 0000
Thomas Wiggans Self Chairman & Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Annexon Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Annexon Biosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Annexon Biosciences‘s full profile, request access.

Request a free trial

Annexon Biosciences ESG

Risk Overview

Risk Rating

Updated May, 18, 2022

36.64 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 14,912

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 965

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 455

Rank

00.00

Percentile

To view Annexon Biosciences’s complete esg history, request access »